Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Hisashi Majima"'
Autor:
Kazuo Tamura, Hisanobu Niitani, Masao Oguro, Ryuzo Ohno, Kazumi Sanpi, Hisashi Majima, Tohru Masaoka, Ikuro Kimura, Jiro Inagaki, Yozo Suzuoki, Kazuo Ota, Tohru Nakamura, Tamotsu Miyazaki, Makoto Ogawa, Kazumasa Yamada, Kiyoji Kimura
Publikováno v:
Cancer Chemotherapy and Pharmacology. 36:189-194
A phase I study of NKT-01 (deoxyspergualin), which is a derivative of an antitumor antibiotic, spergualin, was performed by a cooperative study group. NKT-01 was given intravenously by 3-h infusion. The effect of single administration was studied pri
Publikováno v:
The Japanese journal of surgery. 21(3)
A 28 year old man suffering from calcifying carcinoma of the stomach underwent a gastrectomy which was histologically classified as being a noncurative resection. As postoperative adjuvant chemotherapy, he received 116 mg of Mitomycin C and 454.8 g o
Autor:
Kohkichi Hayashida, Yuji Miura, Tetsuo Taguchi, Hisashi Majima, Yoshihisa Arai, Ryunosuke Kanamaru, Masakazu Yokoyama, Akira Wakui, Michihiro Ohmichi, Tadatsugu Ohno, Takashi Shimoyama, Shigeyuki Takeyama
Publikováno v:
Journal of Pharmacobio-Dynamics. 10:523-527
A new nitrosourea antitumor agent TA-077, 1-(2-chloroethyl)-3-isobutyl-3-(beta-maltosyl)-1-nitrosourea, was intravenously administered to 15 cancer patients at doses ranging from 7 to 100 N (1 N = 30 mg/m2) in a phase I clinical trial. Time courses o
Autor:
Akira Wakui, Tetsuo Taguchi, Hisashi Majima, Tatsuo Saito, Shoji Suga, Ichiro Urushizaki, Kiyoji Kimura, Ota K, Hisanobu Niitani, Hidehito Ichihashi, Takao Hattori, Osahiko Abe, Kiyoshi Inoguchi, Ryuzo Ohno, Kazumasa Yamada, Hisashi Furue, Yozo Suzuoki
Publikováno v:
Cancer Chemotherapy and Pharmacology. 20:223-229
A phase I clinical and pharmacokinetic study of recombinant human tumor necrosis factor (rH-TNF) was conducted in a single dose schedule in 33 patients with advanced cancer. rH-TNF was given by i.v. infusion over 30 min with a starting dose of 1 x 10
Autor:
Ken-ichi Ozeki, Yasunobu Sakai, Takashi Mitsushima, Zen-ichi Henmi, Kazutoshi Horikomi, Hisashi Majima, Kei-ichi Maruyama
Publikováno v:
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 11:27-36
In order to clarify the mechanism of the pollakisuria caused in subjects by 1-hexylcarbamoyl-5-fluorouracil (HCFU), a new .antitumor agent, in a Phase 1 study, the effects of HCFU and its metabolites on a cat bladder movement were studied.HCFU and 1-
Autor:
Akira Wakui, Akira Hoshino, Masao Oguro, Toru Masaoka, Ikuro Kimura, Yasushi Ikeda, Shigeru Shirakawa, Fumimaro Takaku, Ryuzo Ohno, Yuzuru Sugawara, Masanori Shimoyama, Hisashi Majima, Satoshi Yoshikawa, Masami Hirano, Kiyoji Kimura, Masahide Kobayashi, Kaoru Yamagata, Kazumasa Yamada, Harumitsu Mizuno, Yutaka Yoshida, Tatuo Saito, Kiyoshi Konno, Hideo Yamada, Ichita Amaki, Makoto Ogawa
Publikováno v:
Cancer chemotherapy and pharmacology. 20(3)
Eighty-four previously treated adult patients with acute leukemia and malignant lymphoma were treated with (2"R)-4'-O-tetrahydropyranyladriamycin (THP). THP (10-55 mg/m2) was administered by i.v. bolus injection daily for acute leukemia, and accordin
Autor:
Hisashi Majima
Publikováno v:
New Anticancer Drugs ISBN: 9783642813948
Clinical studies of drugs in the treatment of cancer have been divided into three parts: Phase I is a pharmacologic study in which the limiting side effects, a satisfactory route of administration, and dose schedule are determined. Phase II is the sc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b314cbf6d9c90b1c1404be145d4a468
https://doi.org/10.1007/978-3-642-81392-4_6
https://doi.org/10.1007/978-3-642-81392-4_6
Autor:
Hisashi Majima
Publisher Summary This chapter reviews the phase I and preliminary phase I clinical trials of bestatin. The peripheral lymphocyte population from two groups of cancer patients was used, one from preoperative gynecological tumor patients with good per
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::48585c8c8a326dba35bc619c308ff7df
https://doi.org/10.1016/b978-0-08-027993-0.50015-1
https://doi.org/10.1016/b978-0-08-027993-0.50015-1
Autor:
Hisashi Majima
Publikováno v:
New Anticancer Drugs ISBN: 9783642813948
Aclacinomycin A (ACM), a new anthracycline antitumor antibiotic, was isolated in 1974 from a culture of Streptomyces galiaeus MA144-MI by Dr. Umezawa et al. in Japan [3]. The structure of ACM is characterized by an ethyl group at position C-13, methy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::28eea561ba748cbb3965c0ed8a72dd11
https://doi.org/10.1007/978-3-642-81392-4_8
https://doi.org/10.1007/978-3-642-81392-4_8